Company ProfilePremium

Terramera Inc.

Company Profile Analysis

ESOMAR 23 Corporate BadgeISO Certifications Badge
Terramera Inc. - Company showcase

Year Founded & Workforce

2010

29 Employees

Terramera Inc. logo

Terramera Inc. Employee Contacts

13 verified contactsNames, job titles, seniority and locations

View Employee Contacts

Terramera Inc. Overview

Listing status: The input list describes Terramera as a public company. That is incorrect. Terramera describes itself as privately held [Terramera "About Us" page], and no exchange listing, ticker, ISIN or CUSIP exists for it.

Terramera began in 2010 as a neem-based biopesticide start-up. Its first products were consumer and professional bed-bug sprays, the Proof and CIRKIL lines. Over the following decade it built a large patent estate in formulation and active-ingredient delivery, centred on its Actigate™ technology and the IP it bought from Exosect. It raised one of Canada's largest agtech venture rounds (US$48.5M Series B, 2019) on a public goal of cutting synthetic chemical loads in agriculture by 80% by 2030. A financing collapse in mid-2022 forced a strategic reset. Under CEO Nate Kelly, Terramera restructured into what BetaKit (March 2026) describes as an IP holding company. It now incubates and holds equity in independent spinouts: Miraterra, which does soil chemistry, biology and remote sensing, and Catalera BioSolutions, which develops biological fungicides, insecticides and miticides. Terramera's value now rests mainly on its patent portfolio (company-stated at more than 350 patents), its minority and partial stakes in these ventures, and its Indian neem supply operation. Operating revenue is now largely earned by the spinouts.


Company's own description. Terramera's current "About Us" page says the company advances agricultural innovation by building independent, science-based companies. It names Catalera BioSolutions and Miraterra as its spinouts and confirms it is privately held and based in Vancouver. An earlier version of the same page described two internal divisions. The first was "Green Chemistry Solutions," a formulation platform combining machine-learning design, more than 350 delivery and stabilization patents, and rapid prototyping. The second was Miraterra, a soil measurement platform claiming parts-per-million accuracy [Terramera About Us, both versions].

Independent characterization. Terramera has gone through three business models.

  1. 2010 to about 2016: consumer and professional biopesticides. The company sold neem-based sprays for bed bugs and dust mites at retail (Proof, sold through retailers including Target) and to pest-control professionals (CIRKIL). It integrated backward into neem supply by buying Plasma Power, an Indian cold-pressed neem oil producer [TechCrunch 2019; PCT Online].

  2. 2016 to 2022: agricultural biologicals and an AI/formulation platform. Most staff moved to agriculture; by 2019 more than 90% of the team was focused on it [BCBusiness 2019]. The company launched the EPA-registered RANGO (2018) and SOCORO (2023) and licensed and partnered its Actigate delivery technology. It also expanded into digital agriculture and soil-carbon measurement (the Terramera Intelligence Engine), which was heavily grant-funded.

  3. 2023 to present: IP holding company and venture builder. After its 2022 financing fell through, the company split its "many businesses in one" into separately financed spinouts. Miraterra (soil) launched in January 2023 and Catalera (biologicals) in May 2024. Terramera kept equity stakes, the core IP estate and the Indian neem operation [Vancouver Tech Journal, Mar 2023; BetaKit, Mar 2026].

Revenue model. Terramera has never disclosed revenue figures; the founder declined to discuss revenue in 2019 [BCBusiness 2019]. Its historical and current revenue types are:

Value-chain position. Terramera sits upstream, in active-ingredient sourcing (neem and karanja) and in formulation and delivery-technology IP. Through Catalera it reaches crop-protection products sold via distributors to growers. Through Miraterra it reaches measurement infrastructure sold mainly to soil labs rather than directly to farmers [AgTechNavigator, Jul 2025].

Customer types and end markets. These are specialty-crop and row-crop growers (organic and conventional), pest-management professionals, consumers (household pests), agricultural input companies (licensing and co-development), soil-testing laboratories, agronomists, and food and supply-chain companies (Miraterra's "soil-to-table" positioning). Government agencies are a further group, as funders and potential standard-setters for soil carbon.

Strategy

Stated strategy themes.

Historical (2019–2022): "Unlock the intelligence in nature." Reduce global synthetic chemical loads in agriculture by 80% while raising farm productivity by 20% by 2030 [Built In; ImpactAlpha 2019]. Use AI, computational chemistry and Actigate to make biologicals competitive with synthetics. Build a soil-carbon measurement standard to enable farm carbon credits [SDTC release 2021].

Current (2023 onward): Make agriculture "work with nature" by building independent companies grounded in deep science. Turn the patent estate into focused, separately capitalized ventures [Terramera About Us; BetaKit 2026]. In 2023 Manhas described the earlier structure as effectively running many businesses inside one company, and said this hurt market understanding and fundraising [Vancouver Tech Journal 2023].

ESG commitments. The 80/20 by 2030 pledge remains on Terramera's legacy materials. No updated progress metrics have been published.

Cost programs. The 2023 restructuring under Kelly is confirmed [BetaKit 2026], but no targets or savings were disclosed.

Medium-term financial targets / guidance: None published.

Products & Services

Crop protection (now commercialized by Catalera BioSolutions)

ProductDescription and capabilitiesTarget customerLaunch / registrationPricingSource
RANGO®Broad-spectrum plant-based insecticide, fungicide and miticide built on a proprietary formulation. Controls aphids, mites, thrips, worms, whiteflies, botrytis, fusarium and powdery mildew. Zero-day pre-harvest interval; 4-hour re-entry. OMRI-listed.Specialty-crop growers (vegetables, fruit, berries and grapes, tree crops, ornamentals, greenhouse)EPA registration and launch 20 Nov 2018; California approval Oct 2019—Terramera press release 2018; AgbioInvestor
SOCORO®Broad-spectrum biological insecticide, miticide and fungicide using neem oil plus other bio-actives. For organic and conventional growers. Not registered in Canada as of 2023.Soybean, corn and row-crop growers (US)US launch Apr 2023—BIV, Apr 2023
TRIFECTO®Biopesticide containing 70% cold-pressed neem oil on a proprietary inert carrier that improves in-tank stabilityGrowers in MexicoCOFEPRIS approval c. 2024—CB Insights news; Techcouver 2024
Vaporpad®Professional bed-bug treatmentPest-management professionalsDate n/d—Techcouver, Sep 2024
Microbial bio-insecticide (pipeline)Microbial insecticide in developmentAgricultureExpected launch 2026—Country Guide
Combination bio-insecticide (pipeline)Combination biological insecticideAgricultureExpected commercialization 2025 (completion not confirmed)—Country Guide

Consumer and professional legacy lines (Terramera-era)

ProductDescriptionCustomerPeriodCurrent statusSource
Proof® (Proof Spray; bugproof.com)Neem-based, EPA-registered bed-bug and dust-mite spray; company claimed 100% efficacy against bed bugs and eggsConsumers via retailers including Targetc. 2013 onward—BioSpace (S2G release); TechCrunch 2019
CIRKIL® (cirkil.com)Professional-grade neem-based pest-control productsPest-control operatorsc. 2014 onward—BioSpace; PCT Online
neem.com productsNeem consumer and raw-material salesConsumers and manufacturers2010s—BioSpace

Raw materials (Terramera Biosciences India)

ProductSpecification (company-stated)CustomerSource
100% pure cold-pressed neem oilPatented cold-press extraction; filtered to 5 microns; azadirachtin content stated above 3,000 ppmBiopesticide formulators, fertilizer and agri-input firms, cosmeticsShifair 2026
Neem kernel cake (powder and pellet)Organic soil amendmentFertilizer and agricultural buyersShifair 2026
Karanja oil and cakeKaranjin content stated above 20,000 ppmAgri-inputsShifair 2026; PMP

Technology platforms (Terramera-held IP, licensed to or used by spinouts)

PlatformDescriptionYearSource
Actigate™ Targeted Performance technologyGreen-chemistry delivery that carries natural or synthetic actives directly into target cells, so less active ingredient is needed and biologicals perform betterPublic from c. 2018–2019ImpactAlpha 2019; Western Producer 2020
Inspirium®Earlier proprietary technology for stabilizing and delivering plant biochemicals such as neemc. 2016BioSpace (S2G release)
Exosect delivery platform (incl. Entostat-derived tech)About 134 patents and applications for delivering crop-protection actives, including organic-compatible compositionsAcquired May 2019Terramera press release; Dealroom
RNAi technology (ex-CCI)RNA-interference technology for crop protectionAcquired Mar 2019AgbioInvestor
Plant Intelligence Engine™AI-based screening of novel adjuvantsc. 2021CB Insights (MBI release excerpt)
Terramera Intelligence EngineSensors, imaging and analytics for soil-carbon quantification; target cost of about US$5 per acre2021–2022BetaKit 2022; Terramera press release 2021

Soil intelligence (now Miraterra)

OfferingDescriptionCustomerLaunchSource
enrichSoil (original product)Real-time soil analysis of N, P, K and C. The company claimed 99% accuracy versus 40–60% for conventional methods.Farmers, agronomistsLimited commercial launch planned 2023Techcouver, Jan 2023
Miraterra DigitizerRaman-spectroscopy instrument using multiple lasers, signal processing and AI to measure soil chemistrySoil-testing labs worldwide2023 onwardBetaKit 2026; AgTechNavigator 2025
Trace Genomics products (acquired)DNA-based soil biology testing, including shotgun metagenomics and pathogen panelsLegacy Trace customers, e.g., TerraformaAcquired Jul 2025PR Newswire 2025
Remote sensing stackSatellite and LIDAR imaging decoded with AIAgribusiness, policymakers2025–2026BetaKit 2026

Financial Narrative

Disclosure status. Terramera is privately held and has not published income statements, balance sheets or cash-flow statements for any fiscal year. Its fiscal year end is also undisclosed. Every line below is therefore "n/d". The tables are kept for automation compatibility.

Income statement

Revenue CAGR: n/d.

Disclosed capital inflows (best available financial proxy)

The only quantitative financial data in the public domain are financing and grant announcements. They are shown by calendar year in original currency. Rows mix currencies, so the currency is stated in each row label. Rounds raised by spinouts are listed separately because they did not flow to Terramera's own balance sheet, apart from the enrichAg seed, which was structured at subsidiary level.

Notes:

  • The 2019 Series B is reported as US$45M at announcement [BusinessWire, Sep 2019], extended to US$48.5M by ArcTern [Techcouver]. Canadian-dollar reports conflict: C$59.5M [BetaKit 2019] and C$64.1M [BetaKit 2022].

  • 2020: C$0.3M Innovate BC Ignite award, held jointly with SFU [Terramera newsroom].

  • 2022: C$1M BC ICE Fund plus C$2M AgriClean Tech [BetaKit 2022; Vancouver Tech Journal 2023].

  • 2023 bridge note amount: n/d [Vancouver Tech Journal, Mar 2023].

  • Miraterra extension: closed October 2025; FCC also provided undisclosed debt; Miraterra's total funding is nearly C$40M [BetaKit, Mar 2026].

  • Catalera: initial close Sep 2024; Canadian-dollar coverage puts the first tranche at C$8.8M (US$6.5M) [BetaKit 2024].

Commentary. No audited trend analysis is possible. The qualitative pattern is still clear. Terramera was capital-intensive and grant-supported from 2019 to 2022, with heavy R&D across delivery chemistry, AI and soil sensing, and headcount near 135. It then hit a liquidity crisis when a financing failed in summer 2022 [Vancouver Tech Journal]. The response was to cut the corporate cost base sharply (third-party headcount profiles imply a fall from about 135 to about 29) and move capital needs to spinouts with their own investors. Within the group, revenue generation now sits mainly at Catalera (in-market biopesticides) and Miraterra (which recently began generating revenue and inherited what its CEO called meaningful revenue from Trace Genomics [BetaKit 2026; AgTechNavigator 2025]). Terramera's own accounts most likely reflect India neem operations, any licensing income, and its equity investments, though none of this has been disclosed.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Group Entities

EntityRelationship to TerrameraActivityLeadershipSource

Terramera, Inc. (Vancouver)

Parent / IP holding company

Holds patent estate, equity stakes, India subsidiary

Nate Kelly (CEO), Karn Manhas (Exec. Chair)

BetaKit 2026

Miraterra Technologies Corporation (formerly enrichAg Technologies)

Partially owned subsidiary; originally majority-owned (Jan 2023); current stake n/d

Soil chemistry (Raman-spectroscopy Digitizer), soil biology (ex-Trace Genomics metagenomics), satellite and LIDAR remote sensing

Nate Kelly (CEO); about 50 staff

BetaKit 2026; Techcouver 2023

Catalera BioSolutions Inc.

Independent spinout; Terramera is a shareholder (stake n/d)

Biological fungicides, insecticides, miticides; RANGO, SOCORO, Vaporpad, TRIFECTO

Matthew Dahabieh (CEO); Nate Kelly (Chair)

BetaKit 2024; BetaKit 2026

Terramera Biosciences (India) Private Limited

Subsidiary (ownership % n/d)

Cold-pressed neem oil, neem kernel cake, karanja oil and cake

—

Shifair 2026

Balance Sheet and Key Financials

Inflow2019202020212022202320242025

Terramera equity: Series B total (USD Mn)

48.5000000

Terramera growth capital: BDC (CAD Mn)

13000000

Terramera government grants (CAD Mn)

—0.37.93000

Terramera bridge note (CAD Mn)

0000—00

Miraterra / enrichAg equity (USD Mn)

000060—

Miraterra seed extension (CAD Mn)

00000016

Catalera Series A target (USD Mn)

0000080

Geography Overview

GeographyActivityEvidence

United States

Main crop-protection market: RANGO (EPA 2018; California 2019) and SOCORO (2023). Consumer Proof retail. Miraterra lab in Ames, Iowa, and Midwest business development.

Terramera and Catalera releases; Miraterra job postings; PR Newswire 2025

Canada

HQ, R&D, greenhouse and growth chambers; soil-carbon pilots funded by SDTC and BC. SOCORO was not registered in Canada as of 2023.

BIV 2023; Terramera releases

Mexico

TRIFECTO registered by COFEPRIS

CB Insights news; Techcouver 2024

India

Neem and karanja production via Terramera Biosciences (India), Chennai

Shifair 2026

Global (labs)

Miraterra sells its Digitizer to soil labs worldwide instead of selling direct to farmers

AgTechNavigator 2025

Capital Markets

MetricFY2021

Item

Status

Analyst consensus

None (no coverage)

Dividend policy

None disclosed

Credit ratings (Moody's / S&P / Fitch)

Not rated

Debt maturity profile

n/d. A 2023 bridge note exists (terms n/d); FCC debt sits at Miraterra, not the parent [BetaKit 2026].

Private valuation marks

n/d for Terramera. Dealroom shows an algorithmic enterprise-value range of US$26–39M for Catalera; this is a model estimate, not a transaction price.

Secondary markets

Caplight lists Catalera; no pricing visible

Analyst Conclusions

Management guidance: None published at the Terramera level.

  • Miraterra plans to use its 2025 extension to accelerate Digitizer deployment, demonstrate full-stack soil measurement and advance its technology [BetaKit 2026].

  • Catalera targets new biological launches, including a microbial bio-insecticide in 2026 [Country Guide].

Consensus growth expectations: None (no coverage).

Bull case

  1. Option value in two focused ventures. Miraterra now combines chemistry, biology and remote sensing, has about 50 staff, is generating revenue, and has nearly C$40M raised from credible investors. A successful scale-up or strategic sale would revalue Terramera's partial stake.

  2. Monetizable IP. More than 350 delivery and stability patents, plus the Exosect estate, give the company licensing and sale leverage as majors race to make biologicals perform consistently. The 2021 Marrone collaboration is a proof point.

  3. Lean parent with real assets. After restructuring, the parent's cost base appears much lower (about 29 staff per a third-party profile), while it keeps an operating Indian neem business and equity in Catalera's in-market products (RANGO, SOCORO, TRIFECTO, Vaporpad).

Bear case

  1. Opaque and diluted economics. No financials, unknown stake sizes, and repeated subsidiary rounds mean Terramera shareholders may own a shrinking slice behind investors with liquidation preferences.

  2. Track record of over-promising. The 80/20-by-2030 goal, the C$730M Global Centre and soil-carbon cost targets have no published progress. The 2022 financing collapse shows fragility.

  3. Crowded, capital-hungry markets. Biologicals face efficacy skepticism and competition from majors with deep pockets. Soil MRV depends on carbon-credit demand that has disappointed, and Catalera's US$8M Series A is small against registration costs.

Key catalysts and monitorables (next 12 months)

Analyst verdict.

Terramera, Inc. is not the listed company the input list suggests. It is a private Vancouver venture builder and IP holding company, and analysis has to treat it as such. For about a decade it was a much-praised Canadian agtech champion. It raised a US$48.5M Series B, won national innovation awards and set out a sweeping mission to cut synthetic pesticide use 80% by 2030. Much of that vision depended on continuous access to capital. When a financing fell through in summer 2022, the company's spread across consumer pest control, agricultural biologicals, AI discovery, soil carbon and a proposed C$730M research centre became a weakness.

The restructuring since 2023 under CEO Nate Kelly is a reasonable response. Moving soil intelligence into Miraterra and biologicals into Catalera gave each business its own investors, narrower goals and a credible management team. It also left the parent as a holder of patents and partial equity stakes. Miraterra is the more visible success: it bought Trace Genomics' assets in 2025, closed a C$16M extension, and now has a revenue-generating chemistry, biology and remote-sensing stack. Catalera has real registered products but a modest capital base for a regulation-heavy industry.

For an investor, counterparty or acquirer, Terramera's value depends on three unknowns: the size and preference ranking of its stakes in the spinouts, the licensing yield of its 350-plus patents, and the economics of its Indian neem business. None of these is disclosed. Without them, no defensible valuation can be set. On balance, Terramera is best viewed as a speculative, illiquid holding vehicle with real underlying technology and meaningful upside if either spinout reaches a strategic exit, alongside material dilution and transparency risks. Due diligence should start with cap-table and IP-assignment documents. Public data cannot settle the question.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameRoleTenureBackgroundSource

Nate Kelly

CEO, Terramera; CEO and board member, Miraterra; Chair, Catalera

Since Mar 2023

About 20 years of building and scaling companies including Tesla (led Model S supply chain), Microsoft and Glowforge; agricultural-community background in Colombia, the US and Canada; based in Santa Barbara as of 2023

Vancouver Tech Journal 2023; BetaKit 2026; AgTechNavigator 2025

Karn Manhas

Founder; Executive Chair

Founder 2010; CEO 2010–Mar 2023; Exec. Chair since Mar 2023 (current status not reconfirmed in 2026 sources)

Former BC MLA (elected 2001 at 24); law degree; McGill; biology background; board member of Qu Biologics

Vancouver Tech Journal 2023; BCBusiness; Techcouver

Jeff Booth

Senior independent non-executive director (from Mar 2023); previously Chairman (from Sep 2019)

Board since at least 2019

Tech entrepreneur and author

ImpactAlpha 2019; Vancouver Tech Journal 2023

Matthew Dahabieh

Former SVP and Head of Green Chemistry Solutions; now CEO of Catalera

Left with the Catalera spinout, May 2024

Formulation and biologicals leader

BetaKit 2024

Travis Good

Former CTO

c. 2020

—

BetaKit 2020

Graeme Herring

Former VP, Intellectual Property Strategy

c. 2019

—

Terramera press release 2019

Craig Hughes

Former President

Dates n/d

Ex-TELUS, Siemens, QuickMobile

MarketScreener

Executive Leadership Team — Dr. Adrian Percy

NameBodyBackgroundSource

Dr. Adrian Percy

Chair, Science & Technology Advisory Council

Former global head of R&D, Bayer Crop Science; CTO of UPL

Techcouver

Dr. Markita Landry

Science & Technology Advisory Council

Academic scientist

Techcouver

Tom Chi

Science & Technology Advisory Council

Later founding partner of At One Ventures (Miraterra lead investor)

Techcouver; Fertilizer Daily 2025

Nancy Roman

Strategic Advisory Board

Food-policy executive

Techcouver

Stewart Beck

Strategic Advisory Board

Former President and CEO, Asia Pacific Foundation of Canada; 31-year diplomat

Techcouver

Santa Ono

Strategic Advisory Board

University president

Techcouver

Unnamed climate-policy expert

Strategic Advisory Board

—

Techcouver

Major Shareholders

InvestorTypeRoundsStake

S2G Ventures / S2G Investments

VC (Chicago)

Series A lead (2016); Series B co-lead (2019); Catalera Series A lead; Miraterra investor

—

Ospraie Ag Science

Strategic ag investor

Series B co-lead (2019)

—

BDC Capital

Crown corporation

C$13M growth capital (2019)

—

ArcTern Ventures

Cleantech VC

US$3.5M Series B extension

—

Export Development Canada

Crown corporation

Listed investor

—

Innovate BC

Provincial agency

Grants

—

Harmonix Fund

Fund

Listed investor

—

At One Ventures

Climate VC

enrichAg/Miraterra seed lead (2023) and extension lead (2025)

Subsidiary level; n/d

Sitka Foundation; iSelect; Farm Credit Canada

Foundation, VC, crown lender

Miraterra investors

Subsidiary level; n/d

Karn Manhas

Founder / insider

——

Competitive Landscape

Key Competitors

CompetitorTypeRelevance

Bayer Crop Science

Global major

Biologicals pipeline and partnerships; formulation scale

Syngenta (Syngenta Biologicals)

Global major

Large biologicals portfolio

Corteva Agriscience

Global major

Expanded biologicals via acquisitions (Stoller, Symborg)

BASF Agricultural Solutions

Global major

Biologicals and formulation

FMC Corporation

Major

Plant Health / biologicals unit

UPL (NPP – Natural Plant Protection)

Major

Natural and biological solutions; ex-CTO Adrian Percy was a Terramera adviser

Bioceres / ProFarm (formerly Marrone Bio)

Mid-cap

Direct biopesticide competitor and former Terramera partner

Certis Biologicals

Private / subsidiary

Neem-based and microbial biopesticides in the US

Koppert

Private

Biological control leader

Vestaron; Provivi; Solasta Bio

Venture-stage

Peptide, pheromone and novel bio-insecticides

Neem-oil formulators (e.g., AzaMax/Parry-type products)

Various

Direct neem-based competition

Pattern Ag

Venture

Soil DNA and biology-based agronomy

Yard Stick PBC

Venture

In-field soil-carbon spectroscopy probe

EarthOptics

Venture

Ground-penetrating sensing for soil carbon and compaction

Perennial; Regrow

Venture

Remote-sensing and model-based soil carbon MRV

Conventional soil labs (e.g., Waypoint, Ward)

Incumbent

Wet-chemistry testing; also a possible channel for the Digitizer

Peer Comparison FY2024

MetricTerramera (FY n/d)Bayer Crop Science (FY2024)Corteva (FY2024)FMC (FY2024)

Revenue

—

about EUR 22.3bn

about USD 16.9bn

about USD 4.2bn

Revenue growth

—

Negative

Slightly negative

Negative

EBITDA margin

—

Low-20s %

High-teens %

Low-20s %

R&D intensity

n/d (historically R&D-led; more than half of 2019 hiring plan was R&D)

About 10% of sales

About 8% of sales

About 7% of sales

Recent Developments

Most developments occur at the spinout level.

Not found in the window: * Terramera-level financing, executive changes, litigation, regulatory actions, layoffs or product registrations.

Company Snapshot

29

Employees

2010

Founded

Vancouver, Canada

Headquarters

SWOT Analysis

Strengths

  • Deep IP estate: More than 350 patents claimed for delivery and stability [Terramera About Us]; 134 acquired from Exosect [press release 2019]
  • Registered, in-market products: RANGO EPA-registered 2018 and California-approved 2019; SOCORO US 2023; TRIFECTO Mexico c. 2024
  • Vertically integrated active-ingredient supply: Plasma Power / Terramera Biosciences India, described as the only EPA-registered cold-pressed neem source [PCT Online]
  • Repeated backing from strong ag investors: S2G (Series A, Series B, Catalera, Miraterra); Ospraie; BDC; At One; FCC [multiple releases]
  • Spinout model has attracted fresh capital: US$6M (2023) plus C$16M (2025) for Miraterra; US$8M Series A target for Catalera
  • Recognized technical credibility: Global Cleantech 100 (2019); Fast Company World Changing Idea (2020); BC Tech innovation award (2020); C$7.9M SDTC award (2021)

Weaknesses

  • No disclosed revenue or profitability: Founder declined to discuss revenue [BCBusiness 2019]; no financials published
  • History of financing fragility: Summer 2022 financing collapsed at the last minute; bridge note needed in 2023 [Vancouver Tech Journal]
  • Loss of direct operating control: Miraterra only "partially owned"; Catalera "fully independent" with Terramera as a shareholder [BetaKit 2024, 2026]
  • Strategic sprawl in the past: Management said the company ran many businesses in one [Vancouver Tech Journal 2023]; the C$730M Global Centre (2020) was never realized
  • Sharp headcount contraction: About 135 staff (2020) to about 29 (2026 third-party profile)
  • Concentrated leadership: One person is CEO of the parent, CEO of Miraterra and chair of Catalera [BetaKit 2026]

Opportunities

  • Miraterra full-stack soil measurement: Digitizer plus Trace DNA biology plus satellite and LIDAR; about 50 staff and recently revenue-generating [BetaKit 2026]
  • Catalera pipeline launches: Microbial bio-insecticide expected 2026; combination product planned 2025 [Country Guide]
  • Licensing the delivery IP to majors: 2021 Marrone Bio collaboration as a template [GlobeNewswire]
  • Latin American expansion: TRIFECTO COFEPRIS registration in Mexico
  • Neem export markets in Asia: India subsidiary marketing at China's FSHOW (2026 listing)
  • Strategic exits: Majors buying biologicals and soil-data assets; spinout equity could be monetized

Threats

  • Agtech funding drought: The 2022 financing failure shows exposure to capital markets
  • Large incumbents in biologicals: Bayer, Syngenta, Corteva and BASF building or buying biologicals portfolios
  • Dilution of Terramera's stakes: Further Miraterra and Catalera rounds (C$16M in 2025; Catalera Series A) dilute the parent
  • Carbon-market weakness: The original 2021 soil-carbon thesis (C$7.9M SDTC) depends on credit demand
  • Regulatory cost and timing: SOCORO not filed in Canada as of 2023 [BIV]; each market requires new registration
  • Neem commoditization: Many neem-based products from low-cost Indian formulators

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Sep 2024 (context)Catalera initial Series A close (S2G lead; FCC Capital's first deal) PR NewswireValidates the spinout model; Terramera keeps equity
Q4 2024 (context)Planned final close of Catalera Series A FCC releaseCompletion not confirmed publicly
7 Jul 2025Miraterra acquires the assets of Trace Genomics (IP, products, Ames lab) PR NewswireMoves Miraterra from chemistry-only to chemistry plus biology; brings in revenue
9 Jul 2025Kelly says Trace was producing significant revenue and that Miraterra rehired part of the Trace team AgTechNavigatorAccelerates the revenue plan
Jul 2025Miraterra commits to keep serving legacy Trace customers (e.g., Terraforma) TechcouverCustomer continuity; reputational recovery for the Trace brand
Oct 2025Miraterra C$16M seed extension closes (At One lead; S2G, Sitka, iSelect, FCC; plus FCC debt) BetaKit 2026Group-level capital; total raised by Miraterra nears C$40M
17 Oct 2025Aggregator wrongly links "Terramera FRESH" and RIOblanco to Terramera Signalbase vs. GlobeNewswireData-quality risk; not a Terramera event
2025 (expected)Catalera combination bio-insecticide commercialization Country GuidePipeline delivery
Feb 2026Miraterra leaders attend FCC Future of Food event in Ottawa BetaKit 2026Relationship with crown lender and investor
12 Mar 2026Terramera Biosciences (India) listed as exhibitor promoting neem and karanja products for China's FSHOW fertilizer exhibition ShifairConfirms India subsidiary is active and seeking export customers
25 Mar 2026Miraterra publicly announces the C$16M extension; now about 50 staff and recently revenue-generating BetaKitConfirms Terramera's IP-holding-company status and partial ownership
2026 (expected)Catalera microbial bio-insecticide market entry Country GuideKey 2026 catalyst for Catalera's value

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Income Statement

1 chart
Key Financials: Terramera growth capital: BDC fell from CAD 13 Mn in 2019 to CAD 0 Mn in 2025.
Terramera Inc. — Key Financials
Series (CAD Mn)2019202020212022202320242025
Terramera growth capital: BDC13000000
Terramera government grants—0.37.93000
Miraterra seed extension00000016

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Sources

Sources

  1. Terramera, "About Us" (current and archived versions) (terramera.com)
  2. BetaKit, "Miraterra announces $16 million to advance its soil measurement tech," 25 Mar 2026
  3. BetaKit, "Terramera spinout Catalera secures $8.8 million CAD in first Series A tranche," 2024
  4. Vancouver Tech Journal, "Karn Manhas steps down as CEO of Terramera," 14 Mar 2023
  5. Vancouver Tech Journal, "Terramera enrichAg / enrichSoil seed subsidiary," Jan 2023
  6. Techcouver, "With $6 Million Seed Round, Terramera Creates enrichAg…," 12 Jan 2023
  7. AgFunderNews, "Terramera spinout enrichAg officially launches with $6m from At One Ventures," 2023; "Catalera … first close of Series A," 2024
  8. BIV, "Vancouver agri-tech lands $6M in seed financing," Jan 2023; "Terramera launches bio-pesticide in U.S.," Apr 2023
  9. FCC news release / PR Newswire, "Catalera Series A Funding…," 10 Sep 2024
  10. Techcouver, "Terramera Spin Out Catalera BioSolutions Raises Round…," 10 Sep 2024
  11. Country Guide, "Biologicals business Catalera receives funding boost"
  12. PR Newswire / Food Online, "Miraterra Acquires Trace Genomics…," 7 Jul 2025
  13. AgTechNavigator, "Soil measurement company Miraterra bolts on Trace Genomics," 9 Jul 2025
  14. Fertilizer Daily, "Miraterra enhances platform with Trace Genomics acquisition," 8 Jul 2025
  15. Terramera press release, "Terramera Acquires Exosect Crop Protection Technology & IP," 14 May 2019
  16. BusinessWire / BioSpace, "Terramera Raises US$45 Million…," 5 Sep 2019
  17. TechCrunch, "Terramera raises $45 million…," 5 Sep 2019
  18. ImpactAlpha, "Terramera raises $45 million…," Sep 2019
  19. BetaKit, "Terramera raises $59.5 million CAD Series B…," 2019
  20. Techcouver, "Terramera's Series B Round Closes at US $48.5 Million"
  21. Terramera press release / Fruit Growers News, "RANGO launch," 20 Nov 2018
  22. AgbioInvestor, Terramera news tag (CCI RNAi, BDC, California approval, SOCORO, Pluton)
  23. PCT Online and PMP, "Terramera PlantScience acquires Plasma Power"
  24. BioSpace, "Terramera Closes Financing Led By Seed 2 Growth Ventures" (c. 2016)
  25. Terramera press release, "Terramera Awarded $7.9 Million…," 27 May 2021; Techcouver SDTC article
  26. BetaKit, "Terramera receives $1 million from BC…," 2022; KnowESG, 29 Apr 2022
  27. BetaKit, "Terramera looking to build $730 million centre…," Nov 2020; Western Producer, 12 Nov 2020
  28. Terramera press release, "Terramera wins Excellence in Technology Innovation award," 6 Nov 2020
  29. GlobeNewswire / Seed World, "Marrone Bio Innovations Collaborates with Terramera," 16 Aug 2021
  30. BCBusiness profiles of Karn Manhas (2019, 2021)
  31. YPO, "Tech disruptor Karn Manhas alters the future of farming," Aug 2019
  32. Techcouver, advisory board announcements; C.L.I.C. Challenge
  33. CB Insights company profiles (terramera; terramera-inc; financials)
  34. Built In / Built In Vancouver company profile
  35. Unreasonable Group venture profile; Unreasonable job postings (Miraterra)
  36. Pubrio company profile (2026)
  37. VCBacked; Dealroom (Catalera, Exosect); PitchBook (Exosect; TERRAMARA FRESH); Caplight (Catalera)
  38. Shifair, FSHOW exhibitor profile of Terramera Biosciences (India) Pvt Ltd, 12 Mar 2026
  39. GlobeNewswire / Portal Frutícola, "AMFRESH Group Acquires 100% of TERRAMARA FRESH…," 17 Oct 2025
  40. MarketScreener, Craig Hughes insider profile

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.